Source comparison
Comparison: 5-Amino-1MQ vs Other Fat Loss Compounds
Before interpreting the 5-amino-1MQ study in isolation, context matters. How does NNMT inhibition compare to established fat loss mechanisms? 5-Amino-1MQ NNMT inhibition → NAD+ preservation → sirtuin activation → mitochondrial fat oxidation 7% body weight, 30%
This comparison does not assign a generated winner or score.
- Before interpreting the 5-amino-1MQ study in isolation, context matters. How does NNMT inhibition compare to established fat loss mechanisms?
- 5-Amino-1MQ
- NNMT inhibition → NAD+ preservation → sirtuin activation → mitochondrial fat oxidation
- 7% body weight, 30% visceral fat (11 days, mice)
- None published as of 2026
- Dosing, route, duration all extrapolated from animal data
- GW501516 (Cardarine)
- PPAR-delta agonist → upregulates fatty acid oxidation genes
- 5–10% fat mass reduction (4 weeks, mice)
- No controlled human trials
- Rodent carcinogenicity at high doses, not approved for human use
- Semaglutide (GLP-1 agonist)
- Appetite suppression + delayed gastric emptying
- Not applicable (mechanism is caloric deficit)
- 14.9% body weight (68 weeks, STEP-1 trial)
- Requires sustained use, rebound upon cessation, GI side effects
- Yohimbine
- Alpha-2 adrenergic antagonist → blocks lipolysis inhibition
- Modest (2–3% fat mass, human studies)
- Multiple human trials, well-tolerated
- Effect size small, limited to fasted state
- DNP (2,4-Dinitrophenol)
- Mitochondrial uncoupler → forces ATP production inefficiency
- 10–15% body weight (weeks, humans)
- Extensive black-market human use data
- Lethal overdose margin narrow, hyperthermia risk, banned
- The 5-amino-1MQ study result. 7% weight loss in under two weeks with no dietary change. Sits between yohimbine (too weak) and DNP (too dangerous). Its advantage: a plausible, targeted mechanism that doesn't rely on appetite suppression or thermogenic overload. Its disadvantage: zero human data to confirm the effect translates across species.